Tier 2 — strong

Fetal and Neonatal Effects of N-Acetylcysteine When Used for Neuroprotection in Maternal Chorioamnionitis

Dorothea D Jenkins, Donald B Wiest, Denise M Mulvihill, Anthony M Hlavacek, Sarah J Majstoravich, Truman R Brown, Joseph J Taylor, Jason R Buckley, Robert P Turner, Laura Grace Rollins, Jessica P Bentzley, Kathryn E Hope, Andrew B Barbour, Danielle W Lowe, Renee H Martin, Eugene Y Chang
J Pediatr 2016 168:67-76.e6

Bibliography

PubMed
PMID 26545726
PubMed Central
PMC4698030
DOI
10.1016/j.jpeds.2015.09.076
Funding
Funding disclosure was not located in the indexed record reviewed; consult the source publication for the full funding statement.
Competing interests
Competing-interest disclosure was not located in the indexed record reviewed; consult the source publication for the full declaration.

Study snapshot

DesignRandomized controlled maternal-fetal pharmacology trial
ModelHuman
Sample22 mothers and 24 infants
InterventionMaternal NAC versus placebo in chorioamnionitis
DurationPeripartum treatment
EndpointsMaternal-fetal pharmacokinetics; Neonatal safety; Neuroprotection biomarkers

What the study showed, in plain terms

Small maternal-fetal trial evaluating NAC transfer, safety and biological effects in chorioamnionitis.

Key findings

NAC crossed the placenta rapidly and generated preliminary safety and neuroprotection signals.

What this study can and cannot tell us

Very small high-risk obstetric population; cannot support routine pregnancy supplementation.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology